Treatment Of Estrogen And Cardiovascular Disease - amazonia.fiocruz.br

Treatment Of Estrogen And Cardiovascular Disease Video

Patients with Type 2 diabetes and atherosclerotic cardiovascular disease are at increased risk for cardiovascular events. However, less than 3 percent of this population are using the appropriate evidence-based therapies that would reduce this risk, according to findings from a recent analysis of pharmacy and insurance claims data.

Duke Clinical Research Institute | From Thought Leadership to Clinical Practice

Although evidence from clinical trials supports prescribing all three of these therapies to eligible patients, they are profoundly under-used in clinical practice. The findings from the sample of overpatients showed:.

The study team estimates that an increase in prescription of evidence-based therapies to percent over three years could reduce future major adverse cardiovascular events by 4, events in this population ofpatients. Patients, providers, industry, regulators, professional societies, and payers all have a role to play in translating evidence to practice.

February 3, — Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events. The data reinforces the presence of gender disparities seen in other studies, with men more likely to be using evidence-based therapies. However, the study was not powered to determine whether this difference can be attributed to prescribing behavior, patient adherence, or a combination of the two.]